JAMA Medical News August 2025 Medical News Summary
Aug 29, 2025
The discussion highlights the emerging substance 7-hydroxymitragynine (7-OH) and its potential abuse risks, especially among children. There's a deep dive into recent FDA-approved anti-amyloid therapies for Alzheimer's, including real-world patient experiences and the critical role of amyloid plaque detection. Additionally, the complexities of SSRIs during pregnancy are examined, with experts debating the risks versus benefits and the importance of patient counseling in making informed decisions. Tune in for insights that bridge innovative treatments with real-life implications!
AI Snips
Chapters
Transcript
Episode notes
7-OH Is A Potent, Readily Available Opioid-Like Drug
- 7-hydroxymitragynine (7-OH) is a potent opioid-like compound now sold in high concentrations at retail outlets.
- The FDA warns it has high abuse potential and urges scheduling and clinician awareness.
Clinicians Seeing Both Medical And Recreational Use
- Clinicians report 7-OH use among people with chronic pain seeking alternatives and people seeking euphoria.
- Poison centers logged rising cases including pediatric exposures and severe respiratory depression.
Recommend Scheduling And Clinician Vigilance
- The FDA recommends DEA schedule classification and has issued assessments and clinician letters about 7-OH.
- Clinicians should watch for signs of opioid toxicity and counsel patients about availability and risks.